- $458.35m
- $356.31m
- $3.48m
Surrozen, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Surrozen Q2 Operating Income USD -10.37 Million
Surrozen, Inc. expected to post a loss of $1.29 a share - Earnings Preview
Brief: Surrozen Q1 EPS USD -11.65
Biotech firm Surrozen 2025 revenue drops to zero, net loss widens
Brief: Surrozen Inc - On Nov 6, Andrew Maleki Appointed As CFO Effective November 12, 2025 - SEC Filing
Biotechnology firm Surrozen's Q3 net loss widens on higher R&D costs
Brief: Surrozen Q3 EPS USD -8.36
Brief: Surrozen Inc Files For Common Stock Offering Of Up To $50 Million
Brief: Surrozen Q2 EPS USD 2.55
Brief: Surrozen Inc Files For Mixed Shelf Of Up To $150 Million - SEC Filing
Brief: Surrozen Q1 EPS USD -7.43
Surrozen Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Stempoint Capital LP Reports 12.8% Passive Stake In Surrozen Inc As Of Oct 31
Surrozen Inc reports results for the quarter ended in June - Earnings Summary
Surrozen Inc expected to post a loss of $2.71 a share - Earnings Preview
Surrozen Inc expected to post a loss of $2.79 a share - Earnings Preview
Brief: Surrozen Presents Preliminary Results From Phase 1A Study Of Szn-043 In Healthy Volunteers And Patients With A History Of Liver Cirrhosis At The 2024 European Association For The Study Of The Liver (Easl) In Milan
Brief: Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis